BioAtla, Inc.

BCAB

US09077B1044

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:12:32 2024-05-14 pm EDT			5-day change	1st Jan Change
2.675 ^USD	+1.33%		-13.11%	+9.15%

May. 06	BioAtla's Multiple Cancer Drug Candidate Receives FDA Clearance	MT
May. 06	BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors	CI

BioAtla, Inc.(NasdaqGM:BCAB) dropped from Russell 2000 Value Index

June 25, 2021 at 12:00 am EDT

Latest news about BioAtla, Inc.

BioAtla's Multiple Cancer Drug Candidate Receives FDA Clearance	May. 06	MT
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors	May. 06	CI
HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating	Mar. 27	MT
Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
BioAtla, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 26	CI
Transcript : BioAtla, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:45 AM	Jan. 11
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Dec. 21	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	Dec. 21	MT
BioAtla Rallies After CEO Buys 50,000 Shares	Dec. 21	MT
Transcript : BioAtla, Inc. - Special Call	Dec. 17
BioAtla, Inc.(NasdaqGM:BCAB) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types	Dec. 13	CI
Transcript : BioAtla, Inc. - Special Call	Dec. 13
Sector Update: Health Care Stocks Slipping Tuesday Afternoon	Dec. 05	MT
BioAtla Says Clinical Benefits, Safety Profile Support Further Evaluation of Potential Lung Cancer Therapy	Dec. 05	MT
BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	Dec. 05	CI
Top Premarket Decliners	Nov. 27	MT
HC Wainwright Lowers Price Target on BioAtla to $10 From $17, Maintains Buy Rating	Nov. 08	MT
BioAtla, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Transcript : BioAtla, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
JPMorgan Adjusts BioAtla Price Target to $14 From $17, Maintains Overweight Rating	23-09-25	MT
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01	CI
Transcript : BioAtla, Inc., Q2 2023 Earnings Call, Aug 01, 2023	23-08-01
BioAtla, Inc.(NasdaqGM:BCAB) added to Russell Small Cap Comp Value Index	23-06-23	CI
BioAtla, Inc.(NasdaqGM:BCAB) added to Russell 3000 Index	23-06-23	CI

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Companyâs product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

Sector

Biotechnology & Medical Research

Calendar

04:01pm - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.64 USD

Average target price

11.5 USD

Spread / Average Target

+335.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOATLA, INC.	+9.15%	127M
MODERNA, INC.	+27.45%	48.16B
IQVIA HOLDINGS INC.	-0.88%	41.73B
LONZA GROUP AG	+43.45%	41.03B
CELLTRION, INC.	-5.26%	28.77B
ICON PUBLIC LIMITED COMPANY	+10.54%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-22.83%	18.96B
BIO-TECHNE CORPORATION	+8.00%	12.92B
MEDPACE HOLDINGS, INC.	+29.29%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.07%	11.77B

Other Biotechnology & Medical Research

BioAtla, Inc.

Equities

BCAB

US09077B1044

Biotechnology & Medical Research

BioAtla, Inc.(NasdaqGM:BCAB) dropped from Russell 2000 Value Index

Latest news about BioAtla, Inc.

Chart BioAtla, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research